Ad hoc announcement pursuant to Art. 53 KR

Altstätten, 30 October 2024

COLTENE specifies medium-term targets at Capital Markets Day

COLTENE Holding AG, a leading international developer and manufacturer of dental consumables and small equipment, is hosting its Capital Markets Day today at its headquarters in Altstätten SG. CEO Dominik Arnold, together with CFO Markus Abderhalden and CSO Europe & RoW Di Hu, will present the results of the strategy process for 2025-2027 and provide an outlook on the current financial year 2024 as well as on the medium-term targets. 

2025-2027 strategy process: Action plan for profitable growth

As part of its regular strategic cycle, COLTENE has redefined its strategy for the years 2025 to 2027. Building on the solid foundation and core direction of COLTENE, the Board and Management have established an ambitious, focused action and implementation plan to accelerate growth and enhance profitability across the three product groups: Dental Improvement, Treatment Auxiliaries, and Infection Control. This action plan addresses the three key elements: employees, customers, and operations, all of which will be explained in detail on today’s Capital Markets Day.

“We will succeed in our markets by aligning our offerings closely with the needs of our customers in dental practices as well as our distributors. At the heart of our strategy is COLTENE’s vision to empower dentists to preserve and enhance natural teeth. At the same time, we ensure that our portfolio reaches customers efficiently, supported by a targeted marketing strategy tailored to each product group,” commented CEO Dominik Arnold.

Outlook 2024 and medium-term targets through 2027

COLTENE has had a good start to the second half of 2024. For the current financial year 2024, COLTENE confirms the outlook presented during the half-year results announcement in August. Accordingly, revenue growth for 2024 is expected to range between 3-5% year-over-year at constant exchange rates. Additionally, COLTENE anticipates an EBIT margin within the target range of 10-11% for 2024.

Over the medium term, COLTENE expects to outgrow the market with an overall organic revenue growth rate of 3-5% per year, an EBIT margin of 13-15% and a ROCE of over 25% by 2027. The medium- to long-term target for the EBIT margin remains unchanged at 15%.

***

CMD 2024 Presentation

The full presentation of today’s Capital Markets Day is available at invest.coltene.com/financial-publications/presentations.

Sign up for email updates from COLTENE Holding AG at invest.coltene.com.

About COLTENE

COLTENE is an international developer, manufacturer, and seller of dental consumables and small equipment in the areas of Infection Control, Dental Preservation, and Efficient Treatment. COLTENE has state-of-the-art production facilities in the USA, Canada, Germany, France, and Switzerland as well as own sales organizations in all major markets including Europe, North and Latin America, Japan, China, and India. Dentists, DSOs, dental clinics, and dental labs all around the globe trust COLTENE’s high-quality products. The registered shares of COLTENE Holding AG (CLTN) are listed on SIX Swiss Exchange. Learn more about COLTENE and our products at www.coltene.com.

This written statement and oral statements or other statements made, or to be made, by us contain forward-looking statements that do not relate solely to historical or current facts. These forward-looking statements are based on the current plans and expectations of our management and are subject to a number of uncertainties and risks that could significantly affect our current plans and expectations, as well as future results of operations and financial conditions. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.